

Original Research Article

Molecular interaction between the antibiotic, Gentamicin and the cancer protein target, TP53 using Insilico tools

Abstract

The most prevalent mutation in hepatocellular carcinoma (HCC), TP53 mutations impacts the course and prognosis of HCC. We employ 3D Insilico drug docking techniques to make the possible mutant target protein TP53 interact with benzene acetic acid (Gentamicin) and non-steroidal anti-inflammatory drugs (NSAIDs). To carry out drug docking techniques, the translated amino acid sequence and three-dimensional chemical compound were obtained from the NCBI database. The use of sophisticated 3D molecular visualization tools was employed in post-docking experiments. The use of sophisticated 3D molecular visualization tools was employed in post-docking experiments. The docking study results unequivocally show that gentamicin directly suppresses amino acid mutational sites. TP53 and Gentamicin's electrostatic force is depicted in a three-dimensional manner using notions from molecular dynamics techniques. In the end, we determined that gentamicin, an Antibiotic medication, helps treat liver cancer. Most chemotherapy medications cause pain. Therefore, we advise using Gentamicin, which lessens discomfort while minimizing the symptoms of cancer.

Keywords: HCC, TP53, Gentamicin, and Drug Docking

Introduction

According to data from the Global Cancer Observatory (GLOBOCAN) for 2020, liver cancer ranks tenth among all cancers in India, accounting for 34,743 new cases and 33,793 deaths annually [1]. According to data that is currently available, age-adjusted incidence rates of HCC in India range from 0.7 to 7.5 per 1,000 individuals annually for men and from 0.2 to

2.2 per 1,000 women. In India, the proportion of cirrhotic patients with HCC rises by 1.6% annually. Though less than 5% of people with cirrhosis go on to acquire HCC each year, 90% of HCC cases have a history of cirrhosis [2]. However, the yearly recurrence rate of HCC is 15%–20%, higher than that of any other malignant tumor with a high fatality rate. Male-to-female ratios for HCC presentations in India range from 4:1 and the patients' ages range from 40 to 70. In India, the age-standardized HCC death rate is 6.8/1,00,000 for men and 5.1/1,00,000 for women. HBV is the main etiological factor associated with HCC in India. But as of right now, India lacks access to thorough HCC data [3].

A prominent tumor suppressor gene in humans, TP53, is found on chromosome 17p13.1. With 11 exons that together encode 393 amino acid residues, it is one of the most commonly changed genes in African-Asian cultures [4]. Because it is necessary to maintain both the integrity of the genome and intracellular homeostasis, it is known as the guardian of the genome. Numerous processes related to cell survival are triggered by it, such as differentiation, senescence, apoptosis, cell cycle arrest, and DNA damage [5]. In a physiological sense, the p53 protein is kept low and unstable by negative regulatory factors in cells [6]. Furthermore, TP53 can mutate by point mutation, deletion, frameshift, rearrangement, and other mechanisms in all types of cancer [7]. The lengthy half-life and high stability of the encoded P53 protein are caused by a mutation in TP53; eventually, the protein accumulates in the nucleus and loses its monitoring capacity.

A mutant p53 mutation can cause cancer by improving migration, invasion, and metastasis. It can also make cells more resistant to chemotherapy and more likely to multiply [5]. Today, Liver cancer is a challenge faced by medical and surgical oncologists. Identification of a potential cancer target is a major task in the field of pharmacology and drug design. Our research work elucidates how the existing general antibiotics help in reducing the effects of hepatocellular carcinoma-induced protein TP53.

Methodology

HCC Protein selection

The data was obtained from the NCBI Genpept database (AZI94701.1_TP53_HUMAN). Gentamicin (CID: 3467) was obtained from NCBI- PubChem [8]

(<https://pubchem.ncbi.nlm.nih.gov>) in order to do molecular drug docking research. A powerful molecular visualization tool named Discovery Studio was used to predict Three-Dimensional structures.

Drug Docking

HDOCK, an automated molecular drug docking server (<http://hdock.phys.hust.edu.cn/>) [9] has been used in studies on molecular drug docking. Using a 3D molecular dynamics methodology, the molecular affinities of Gentamicin and the cancer protein TP53 (tumor protein p53) in human Hepatocellular Carcinoma (HCC) were ascertained.

3D Ligand interaction studies

The Discovery Studio software was used to conduct post-docking studies. The molecular dynamics concept was utilized to thoroughly examine the Three-dimensional image based on the docking score (3D H-bond/Electrostatic interactions).

Results

TP53 gene-coded protein sequence

>AZI94701.1 tumor protein p53, partial [Homo sapiens]

CQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGEQG
Q




Fig.1. Complex form of Gentamicin with tumor protein, TP53 using H-Dock server showing the corresponding binding scores.




Fig.2. 3D structure of Gentamicin in ball and stick model viewed using Discovery Studio Software.




Fig.6. Complex form of Gentamicin with TP53 showing 3D hydrophobic interaction.




Fig.7. Complex form of Gentamicin (green color) with TP53 (yellow color) showing the electrostatic force of attraction using Discovery Studio software.

Discussion

The length of the TP53 gene-coded protein sequence amino acids length is 58 aa. This sequence was validated for analysing the drug docking studies. The most significant tumor suppressor gene is thought to be the TP53 gene, which plays a significant role in the development of cancer. The p53 protein is involved in DNA repair, senescence, cell cycle regulation, autophagy, and apoptosis. It also functions as a transcription factor. Evidence links TP53 to aging, longevity, and fertility in addition to cancer. Furthermore, there is increasing evidence linking TP53 genetic variations to environmental adaptation. Pathogenic TP53 mutations or unique TP53 amino acid residues appear to be adaptive for animals exposed to malnutrition or living in cold, hypoxic conditions, respectively. It has recently been established that several cancer genes, including TP53, are subject to positive selection in human tissues that are healthy at the somatic level [10,11,12].

In our research work, we use the potential antibiotic Gentamicin (Fig: 2) in order to introduce it to the tumor protein. The molecular properties of the drug is as follows: (MW: 477.600 g/mol MF: C₂₁H₄₃N₅O₇, 2-[4, 6-diamino-3-[3-amino-6-[1-(methylamino) ethyl] oxan-2-yl] oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol).

The medication we chose, gentamicin, is the antibiotic that is prescribed the most frequently worldwide. In 1963, gentamicin, an aminoglycoside with antibacterial properties, was identified and extracted from *Micromonospora purpurea*. Because of its availability,

affordability, and broad range of activity, it is one of the aminoglycosides that doctors prescribe the most. Although gentamicin works well against gram-positive and gram-negative bacteria, it is most helpful in treating severe gram-negative infections, such as those brought on by *Pseudomonas aeruginosa*. When beta-lactam antibiotics and gentamicin are taken together, there is an additional advantage known as synergy [13,14,15] Fig (1) shows the 3D docking score is -115.32 kcal/mol between Gentamicin and the tumor protein obtained from H-Dock server shown in complex form. The H-bond interactions between Gentamicin and the tumor protein is shown in detailed view using Discovery Studio Software (Fig: 3-7) In this picture, it is well understood that non-covalent interactions have taken place between the Gentamicin chemical structure and the tumor protein, TP53. Hence, it can be mentioned that tumor protein will be downregulated as proved by previous studies. Various previous literature coincides with our docking studies [16,17,18,19,20,21,22,23].

The human genome contains only about 1.5% protein-coding genes, therefore protein-ligand interactions found in traditional paradigms might not be sufficient to meet the urgent needs of illness treatment. Increased quantities of the protein known as the p53 tumor suppressor are present in a wide range of altered cells. It is either undetectable or only slightly present in resting cells, but it is detectable in many proliferating non-transformed cells as well. It is typically absent or mutated in a variety of cancer forms. In certain cancer types, although most likely not all of them, p53 appears to function as a tumor suppressor [24]. The functional domain region of our retrieved protein is 1-52 (PTHR11447: CELLULAR TUMOR ANTIGEN P53). From our findings we prove that the antibiotic, Gentamicin directly interacts with the domain regions. Our research work clearly proved that the amino acids present at the binding region between the drug and the protein are the following: SER: 32, GLN: 31, SER: 32, SER: 32, THR: 21, ARG: 40.

Conclusion

Our research clearly shows how an antibiotic responds to a tumor protein responsible for Hepatocellular Carcinoma (HCC). Our docking results clearly revealed that Gentamicin binds well to the functional domain region of the TP53 protein, where it attaches and suppresses the expression of the liver cancer protein. The binding interaction between gentamicin and the TP53 protein, as determined by docking scores, distinctly clarifies the 3D electrostatic interaction. Thus, we draw the conclusion that gentamicin has the potential to be an antibiotic medication (aminoglycoside) that helps to treat the consequences of cancer. Our insilico

investigation unequivocally demonstrates that gentamicin, an antibiotic medication, may have pharmacological effects on the TP53 liver cancer protein.

References

- 1) Muddu, V. K., & Bonda, A. (2023). Hepatocellular carcinoma in India: Time for a new focus. *Cancer Research, Statistics, and Treatment*, 6(3), 449. https://doi.org/10.4103/crst.crst_277_23
- 2) Garrido, A., & Djouder, N. (2021). Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma. *Trends in Cancer*, 7(1), 29–36. <https://doi.org/10.1016/j.trecan.2020.08.005>
- 3) Panneerselvam, S., Wilson, C., Kumar, P., Abirami, D., Pamarthi, J., Reddy, M. S., & Varghese, J. (n.d.). Overview of hepatocellular carcinoma: From molecular aspects to future therapeutic options. *Cell Adhesion & Migration*, 17(1), 1–21. <https://doi.org/10.1080/19336918.2023.2258539>
- 4) Qu, J., Lu, W., Chen, M., Gao, W., Zhang, C., Guo, B., & Yang, J. (2020). Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer. *Experimental and Therapeutic Medicine*, 20(5), 1–1. <https://doi.org/10.3892/etm.2020.9145>
- 5) Yu, S., Ji, G., & Zhang, L. (2022). The role of p53 in liver fibrosis. *Frontiers in Pharmacology*, 13. <https://www.frontiersin.org/articles/10.3389/fphar.2022.1057829>
- 6) Blandino, G., & Di Agostino, S. (2018). New therapeutic strategies to treat human cancers expressing mutant p53 proteins. *Journal of Experimental & Clinical Cancer Research*, 37(1), 30. <https://doi.org/10.1186/s13046-018-0705-7>
- 7) Wu, Q., Zhang, K., Jiang, S., Fu, L., Shi, Y., Tan, R., Cui, J., & Zhou, Y. (2020). p53: A key protein that regulates pulmonary fibrosis. *Oxidative Medicine and Cellular Longevity*, 2020. <https://www.hindawi.com/journals/omcl/2020/6635794/>

- 8) Sunghwan Kim, Jie Chen, Tiejun Cheng, Asta Gindulyte, Jia He, Siqian He, Qingliang Li, Benjamin A Shoemaker, Paul A Thiessen, Bo Yu, Leonid Zaslavsky, Jian Zhang, Evan E Bolton, PubChem in 2021: new data content and improved web interfaces, *Nucleic Acids Research*, Volume 49, Issue D1, 8 January 2021, Pages D1388–D1395, <https://doi.org/10.1093/nar/gkaa971>
- 9) Yan, Y., Tao, H., He, J. et al. The HDOCK server for integrated protein–protein docking. *Nat Protoc* 15, 1829–1852 (2020). <https://doi.org/10.1038/s41596-020-0312-x>
- 10) Voskarides K, Giannopoulou N. The Role of TP53 in Adaptation and Evolution. *Cells*. 2023 Feb 3;12(3):512. doi: 10.3390/cells12030512. PMID: 36766853; PMCID: PMC9914165.
- 11) Sakaguchi S, Nakagawa N, Wahba HM, Wada J, Kamada R, Omichinski JG, Sakaguchi K. Highly Similar Tetramerization Domains from the p53 Protein of Different Mammalian Species Possess Varying Biophysical, Functional and Structural Properties. *Int J Mol Sci*. 2023 Nov 22;24(23):16620. doi: 10.3390/ijms242316620. PMID: 38068946; PMCID: PMC10706167.
- 12) Zhang Y, Zhao Z, Li W, Tang Y, Wang S. Mechanism of Taxanes in the Treatment of Lung Cancer Based on Network Pharmacology and Molecular Docking. *Curr Issues Mol Biol*. 2023 Aug 7;45(8):6564-6582. doi: 10.3390/cimb45080414. PMID: 37623233; PMCID: PMC10453041.
- 13) Chaves BJ, Tadi P. Gentamicin. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32491482.
- 14) Block M, Blanchard DL. Aminoglycosides. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31082149.
- 15) Lin LL, Hung JN, Shiu SI, Su YH, Chen WC, Tseng JJ. Efficacy of prophylactic antibiotics for preterm premature rupture of membranes: a systematic review and network meta-analysis. *Am J Obstet Gynecol MFM*. 2023 Jul;5(7):100978. doi: 10.1016/j.ajogmf.2023.100978. Epub 2023 Apr 23. PMID: 37094635.
- 16) Houseini ST, Nemati F, Sattari A, Azadeh M, BishehKolaei R. Design of crRNA to

Regulate MicroRNAs Related to Metastasis in Colorectal Cancer Using CRISPR-C2c2 (Cas13a) Technique. *Cell J.* 2023 May 28;25(5):354-362. doi: 10.22074/cellj.2023.1989121.1223. PMID: 37300297; PMCID: PMC10257061.

- 17) P Astalakshmi, M Basheera John, Kavnilavu G, D Vimala. Identification of the efficiency of Pentane on the bacterial and insecticide proteins of *Aedes aegypti* and *Aeromonas hydrophila* by Insilico methods. *Int J Mosq Res* 2023; 10(3):47-53.
- 18) P Astalakshmi, M Basheera John, Kavnilavu G, D Vimala. In silico study on Hexadecanoic acid against the outer membrane protein transport protein of *Culex quinquefasciatus* and *Aeromonas hydrophila*. *Int J Mosq Res* 2023; 10(4):07-14.
- 19) P Nijanthi, Santhi S, Balaji Munivelan. Molecular dynamics studies on the arginine kinase protein of *Aedes sollicitans*: Against the natural chemical compound, Gedunin. *Int J Mosq Res* 2023; 10(2):10-14.
- 20) Maithreyee S1,*, Prabha V1, Molecular Interactions between Anti-Inflammatory Drug with Colorectal Cancer (MSH2) Protein Using In-silico Studies. *Solovyov Studies ISPU. VOLUME 71, ISSUE 10, 2023.*
- 21) Nithya G, Prabha V. Identification of a plant derivative (*Hibiscus cannabinus*) for mosquito (*Anopheles darlingi*) control using in silico protein-protein docking techniques. *Int J Mosq Res* 2023; 10(4):25-29.
- 22) Balaji Munivelan, Identification of the mutated sites present in the transmembrane regions of SCN1A_HUMAN (Sodium Voltage-Gated Channel Alpha Subunit 1) using Insilico techniques. *Int. J Pharm. Int. Biosci.* 2020; 5(1): 1-6.
- 23) M Suganya, GB Brindha Devi. Comparative study on the effect of the insecticide, Phorate on the COI (Cytochrome oxidase subunit 1) of *Eudrilus eugeniae* and *Aedes aegypti* using in silico techniques. *Int J Mosq Res* 2023; 10(6):39-44.
- 24) Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. *Nat Rev Drug Discov.* 2023 Feb;22(2):127-144. doi: 10.1038/s41573-022-00571-8. Epub 2022 Oct 10. PMID: 36216888; PMCID: PMC9549847.

UNDER PEER REVIEW